Literature DB >> 24919574

CARTs on the road for myeloma.

Marcela V Maus1, Carl H June2.   

Abstract

Chimeric antigen receptors redirect T cells to surface antigens. Discovery and validation of appropriate target antigens expands the possible indications for chimeric-antigen receptor (CAR) T cells. CS1 is expressed at high levels by multiple myeloma cells, but also to some extent on other lymphocytes. CS1 may be a viable target for CAR T cells in multiple myeloma. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24919574      PMCID： PMC4119563          DOI： 10.1158/1078-0432.CCR-14-0721

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

3.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Authors:  F E Davies; N Raje; T Hideshima; S Lentzsch; G Young; Y T Tai; B Lin; K Podar; D Gupta; D Chauhan; S P Treon; P G Richardson; R L Schlossman; G J Morgan; G W Muller; D I Stirling; K C Anderson
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

Authors:  Andrzej J Jakubowiak; Don M Benson; William Bensinger; David S D Siegel; Todd M Zimmerman; Ann Mohrbacher; Paul G Richardson; Daniel E H Afar; Anil K Singhal; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

5.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Authors:  Sagar Lonial; Ravi Vij; Jean-Luc Harousseau; Thierry Facon; Philippe Moreau; Amitabha Mazumder; Jonathan L Kaufman; Xavier Leleu; L Claire Tsao; Christopher Westland; Anil K Singhal; Sundar Jagannath
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression.

Authors:  Jacques Deguine; Béatrice Breart; Fabrice Lemaître; James P Di Santo; Philippe Bousso
Journal:  Immunity       Date:  2010-10-14       Impact factor: 31.745

7.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 8.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

9.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors:  Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal:  Blood       Date:  2007-09-28       Impact factor: 22.113

10.  Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Authors:  Shauna M Collins; Courtney E Bakan; Gina D Swartzel; Craig C Hofmeister; Yvonne A Efebera; Hakju Kwon; Gary C Starling; David Ciarlariello; Shakthi Bhaskar; Edward L Briercheck; Tiffany Hughes; Jianhua Yu; Audie Rice; Don M Benson
Journal:  Cancer Immunol Immunother       Date:  2013-10-26       Impact factor: 6.968
View more
  6 in total

Review 1.  Immune Modulation in Hematologic Malignancies.

Authors:  Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 2.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

Review 3.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691

Review 4.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

5.  Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.

Authors:  Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Franco Pandolfi; James T Kurnick
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

6.  BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.

Authors:  Jiusheng Deng; Dongkyoo Park; Mengchang Wang; Ajay Nooka; Qiaoya Deng; Shannon Matulis; Jonathan Kaufman; Sagar Lonial; Lawrence H Boise; Jacques Galipeau; Xingming Deng
Journal:  Oncotarget       Date:  2016-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.